帕金森病:神经退行性团 在内分泌网膜压力"潜流"下
Xiangrui Kong1,2, Tingting Liu2, Jianshe Wei1,2
1Wushu College, Henan University, Kaifeng 475004, China.
International journal of molecular sciences
|April 17, 2025
概括
细胞内膜网膜应激 (ERS) 是帕金森病 (PD) 发病的一个关键因素. 准ERS途径为PD提供了有前途的治疗策略,可能改善患者的生活质量.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,与内质网膜应激 (ERS) 有着显著的联系.
- ERS是细胞对ER平衡不平衡的反应,由缺氧和蛋白质错折等因素激活.
- 展开的蛋白质响应 (UPR) 途径,包括IRE1,PERK和ATF6,是ERS的核心.
研究的目的:
- 在帕金森病中全面审查ERS在帕金森病中的作用和分子机制.
- 通过临床,动物和细胞证据探索ERS和PD病变发生之间的关联.
- 讨论针对EPS治疗PD的新兴治疗策略.
主要方法:
- 临床研究,动物模型 (Drosophila,小鼠) 和细胞实验的审查.
- 在PD患者的大脑和脑脊液中分析与ERS相关的分子表达.
- 研究ERS,α-synuclein,LRRK2,帕金,PINK1和线粒体功能障碍之间的分子相互作用.
主要成果:
- ERS与PD的发病和疾病进展密切相关.
- 在动物模型中,ESR抑制减轻了多巴胺能神经元损伤.
- ERS与线粒体功能障碍,氧化应激和神经炎症相互作用,加剧神经元损伤.
结论:
- 在PD中,ERS起着至关重要的作用,涉及α-synuclein聚合和LRRK2突变.
- 针对ERS的治疗策略,包括人工智能辅助的药物设计和非药物干预,显示出潜力.
- 对ERS机制的进一步研究对于开发有效的PD治疗至关重要.
相关概念视频
01:17Role of ER in the Secretory Pathway
4.9K
Eukaryotic cells have a special pathway that enables communication between various intracellular membrane-bound compartments and also with the extracellular environment. This pathway is termed as the secretory pathway.
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
4.9K
01:37The Unfolded Protein Response
4.3K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.3K
01:31Regulation of the Unfolded Protein Response
2.3K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.3K
01:32Export of Misfolded Proteins out of the ER
3.3K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.3K
01:29Protein Folding Quality Check in the RER
3.6K
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
3.6K
01:15Parkinson's Disease: Overview
311
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
311